A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03670901 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped The development was stopped due to company's strategy consideration

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL: JHL1101
BIOLOGICAL: MabThera

Sponsor

JHL Biotech, Inc.